Market by Drug Class, Route of Administration, Distribution Channel, and Regional Outlook | Forecast 2024-2032
Anaphylaxis treatment protocols outline steps for prompt recognition and treatment, with immediate administration of epinephrine as the first-line treatment. Thus, the global anaphylaxis treatment market revolves around effective protocols, guidelines, and plans to address this severe and potentially life-threatening allergic reaction. Anaphylaxis treatment guidelines provide instructions for healthcare professionals, while anaphylaxis treatment plans are personalized approaches based on an individual's allergies and risk factors. Anaphylaxis shock treatment focuses on counteracting severe symptoms like low blood pressure and breathing difficulties. Anaphylaxis treatment at home may involve self-administration of epinephrine auto-injectors before seeking emergency care. The demand for anaphylaxis treatment is driven by the increasing prevalence of allergic conditions and the need for reliable management of anaphylactic episodes.
According to the analysis conducted by Triton Market Research, the Global Anaphylaxis Treatment Market is projected to exhibit a CAGR of 8.63 % during the forecast period from 2024-2032.
MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND OPPORTUNITIESÂ
The rising prevalence of allergic conditions and anaphylaxis cases is a significant driver for the global anaphylaxis treatment market. Anaphylaxis, a severe and potentially life-threatening allergic reaction, can be triggered by various factors such as foods, medications, and environmental allergens. The increasing incidence of conditions like asthma, eczema, and food allergies, particularly in developed countries, has contributed to a higher risk of anaphylaxis. Additionally, factors like urbanization, industrialization, and changing lifestyles have led to increased exposure to allergens, further fueling the demand for effective anaphylaxis treatments.
Underdiagnoses and underreporting of anaphylaxis cases pose a significant challenge for the global anaphylaxis treatment market. Anaphylaxis is often misdiagnosed or overlooked due to the lack of awareness and knowledge among healthcare professionals and patients alike. Many individuals, particularly those with mild symptoms, may not seek medical attention, leading to underreporting of cases. Thus, the lack of standardized diagnostic criteria and the variability in symptom presentation can make it challenging to accurately diagnose and report anaphylaxis cases, hindering the adoption of appropriate treatment strategies.
The increasing focus on developing user-friendly auto-injector devices presents a significant opportunity for the global anaphylaxis treatment market. Auto-injectors, which allow for the rapid administration of epinephrine (adrenaline), are crucial in managing anaphylactic reactions. However, existing auto-injectors have faced challenges such as usability issues, needle anxiety, and the risk of accidental injection. Hence, the need for proper training and the potential for medication errors have highlighted the importance of developing more intuitive and user-friendly devices. Notably, the development of auto-injectors with improved portability, ease of use, and enhanced safety features could significantly improve patient adherence and outcomes, driving market growth.
Report scope can be customized per your requirements - Request Free Sample Report
KEY GEOGRAPHIES COVERED:Â
• North America: United States and CanadaÂ
• Europe: United Kingdom, France, Germany, Spain, Italy, Poland, and Rest of EuropeÂ
• Asia-Pacific: China, Japan, India, Australia & New Zealand, South Korea, ASEAN Countries, and Rest of Asia-PacificÂ
• Latin America: Brazil, Mexico, and Rest of Latin AmericaÂ
• Middle East & Africa: Saudi Arabia, Israel, United Arab Emirates, South Africa, and Rest of Middle East & Africa
SEGMENTATION ANALYSIS - ANAPHYLAXIS TREATMENT MARKET
• Market By Drug Class:
o Epinephrine
o Anti-Histamine
o Beta-Antagonist
o Steroid
o Other Drug Classes
Epinephrine, also known as adrenaline, is the first-line treatment for anaphylaxis and is administered via intramuscular injection or through auto-injector devices. It works by constricting blood vessels, relaxing smooth muscles in the lungs to improve breathing, and stimulating the heartbeat. It rapidly reverses the symptoms of anaphylaxis, such as airway constriction, low blood pressure, and other potentially fatal effects. Medical guidelines and recommendations from various health authorities, including the American Academy of Allergy, Asthma & Immunology (AAAAI), the European Academy of Allergy and Clinical Immunology (EAACI), and the World Allergy Organization (WAO), emphasize the importance of prompt administration of epinephrine in the event of anaphylaxis.
• Market By Route Of Administration:
o Parenteral
o Oral
o Other Route Of Administration
The parenteral route involves delivering medications directly into the body to ensure rapid absorption and distribution. Intramuscular (IM) injections are the primary method for administering epinephrine, the first-line treatment for anaphylaxis. Epinephrine auto-injectors and manual injections are designed for IM administration, allowing for the prompt delivery of the medication into the muscle tissue. The IM route facilitates rapid absorption of epinephrine into the bloodstream, counteracting the systemic effects of anaphylaxis, such as airway constriction, low blood pressure, and organ dysfunction. Intravenous (IV) administration is typically used in hospital settings, where trained healthcare professionals can closely monitor patients and administer additional medications, fluids, or supportive treatments as needed.Â
• Market By Distribution Channel:
o Retail Pharmacy
o Hospital Pharmacy
o Online Pharmacy
COMPETITIVE LANDSCAPE:
The competitive landscape helps dive into data about the key players in the Anaphylaxis Treatment industry. The strategic initiatives for each of the companies considered have been covered in detail.
Drug Approval (March 2022): Aquestive Therapeutics Inc
Aquestive Therapeutics Inc announced the USFDA approval of AQST-109, marking the introduction of the first orally delivered epinephrine-based drug for the emergency treatment of allergic reactions.
Launch (2021): British Society for Allergy and Clinical Immunology's Annual Conference
The UK Anaphylaxis Registry was initiated during the British Society for Allergy and Clinical Immunology's Annual Conference (BSACI). Establishing this registry represents a significant step toward enhancing understanding of anaphylaxis and its impact on individuals in the UK. This launch is expected to facilitate the development of new treatments for managing anaphylaxis.
Study (2021)Â
There was a recognized need for novel therapies aimed at modifying the clinical response to problematic meals, thereby reducing the risk of anaphylaxis. Anticipated changes in the clinical threshold for a food allergy response were linked to reductions in specific IgE levels to the relevant food allergen. Currently in Phase 4, the potential FDA approval of this study holds significant implications for the global treatment market.
KEY BENEFITS OF THE REPORT:Â
Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.Â
Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.Â
The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.
The scope of the market report comprises the current scenario of the global application security market, along with the detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2024-2032.
FAQs:Â
Q 1) Are there any medications other than epinephrine used in anaphylaxis treatment?
Other medications like antihistamines and corticosteroids may also be administered to help alleviate symptoms and prevent recurrence.
Q 2) Can anaphylaxis occur in children?
Anaphylaxis can occur in individuals of any age, including children.
Q 3) What are the symptoms of anaphylaxis?
Symptoms may include difficulty breathing, swelling of the face and throat, hives, rapid heartbeat, and a drop in blood pressure.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL ANAPHYLAXIS TREATMENT MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. PORTER’S FIVE FORCES ANALYSIS
2.1.1. THREAT OF NEW ENTRANTS
2.1.2. THREAT OF SUBSTITUTES
2.1.3. BARGAINING POWER OF BUYERS
2.1.4. BARGAINING POWER OF SUPPLIERS
2.1.5. THREAT OF COMPETITIVE RIVALRY
2.2. MARKET MATURITY ANALYSIS
2.3. SUPPLY CHAIN ANALYSIS
2.3.1. RAW MATERIAL PROCUREMENT
2.3.2. MANUFACTURING
2.3.3. DISTRIBUTION
2.3.4. RETAIL AND HEALTHCARE PROVISION
2.4. REGULATORY FRAMEWORK
2.5. KEY BUYING IMPACT ANALYSIS
2.5.1. COST AND PRICING ANALYSIS
2.5.2. PRODUCT EFFICACY AND SAFETY
2.5.3. BRAND REPUTATION AND TRUST
2.6. KEY MARKET STRATEGIES
2.6.1. COLLABORATIONS
2.6.2. PRODUCT LAUNCHES
2.6.3. ACQUISITIONS
2.6.4. BUSINESS DIVESTITURES & EXPANSIONS
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF ALLERGIC CONDITIONS AND ANAPHYLAXIS CASES
2.7.2. GROWING GERIATRIC POPULATION SUSCEPTIBLE TO SEVERE ALLERGIC REACTIONS
2.7.3. INCREASING AWARENESS ABOUT ANAPHYLAXIS MANAGEMENT
2.7.4. FAVORABLE REIMBURSEMENT POLICIES FOR ANAPHYLAXIS TREATMENT
2.8. MARKET CHALLENGES
2.8.1. UNDERDIAGNOSES AND UNDERREPORTING OF ANAPHYLAXIS CASES
2.8.2. STRINGENT REGULATORY REQUIREMENTS FOR PRODUCT APPROVAL
2.8.3. HIGH TREATMENT COSTS AND LIMITED ACCESS IN DEVELOPING REGIONS
2.9. MARKET OPPORTUNITIES
2.9.1. INCREASING FOCUS ON DEVELOPING USER-FRIENDLY AUTO-INJECTOR DEVICES
2.10. ANALYST PERSPECTIVE
3. GLOBAL ANAPHYLAXIS TREATMENT MARKET – BY DRUG CLASS
3.1. EPINEPHRINE
3.2. ANTI-HISTAMINE
3.3. BETA-ANTAGONIST
3.4. STEROID
3.5. OTHER DRUG CLASSES
4. GLOBAL ANAPHYLAXIS TREATMENT MARKET – BY ROUTE OF ADMINISTRATION
4.1. PARENTERAL
4.2. ORAL
4.3. OTHER ROUTE OF ADMINISTRATION
5. GLOBAL ANAPHYLAXIS TREATMENT MARKET – BY DISTRIBUTION CHANNEL
5.1. RETAIL PHARMACY
5.2. HOSPITAL PHARMACY
5.3. ONLINE PHARMACY
6. GLOBAL ANAPHYLAXIS TREATMENT MARKET – BY REGIONAL OUTLOOK
6.1. NORTH AMERICA
6.1.1. MARKET BY DRUG CLASS
6.1.2. MARKET BY ROUTE OF ADMINISTRATION
6.1.3. MARKET BY DISTRIBUTION CHANNEL
6.1.4. COUNTRY ANALYSIS
6.1.4.1. UNITED STATES
6.1.4.1.1. UNITED STATES ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.1.4.2. CANADA
6.1.4.2.1. CANADA ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.2. EUROPE
6.2.1. MARKET BY DRUG CLASS
6.2.2. MARKET BY ROUTE OF ADMINISTRATION
6.2.3. MARKET BY DISTRIBUTION CHANNEL
6.2.4. COUNTRY ANALYSIS
6.2.4.1. UNITED KINGDOM
6.2.4.1.1. UNITED KINGDOM ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.2.4.2. GERMANY
6.2.4.2.1. GERMANY ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.2.4.3. FRANCE
6.2.4.3.1. FRANCE ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.2.4.4. SPAIN
6.2.4.4.1. SPAIN ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.2.4.5. ITALY
6.2.4.5.1. ITALY ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.2.4.6. POLAND
6.2.4.6.1. POLAND ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.2.4.7. REST OF EUROPE
6.2.4.7.1. REST OF EUROPE ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.3. ASIA-PACIFIC
6.3.1. MARKET BY APPLICATION
6.3.2. MARKET BY DRUG CLASS
6.3.3. MARKET BY ROUTE OF ADMINISTRATION
6.3.4. MARKET BY DISTRIBUTION CHANNEL
6.3.4.1. CHINA
6.3.4.1.1. CHINA ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.3.4.2. JAPAN
6.3.4.2.1. JAPAN ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.3.4.3. INDIA
6.3.4.3.1. INDIA ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.3.4.4. SOUTH KOREA
6.3.4.4.1. SOUTH KOREA ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.3.4.5. ASEAN COUNTRIES
6.3.4.5.1. ASEAN COUNTRIES ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.3.4.6. AUSTRALIA & NEW ZEALAND
6.3.4.6.1. AUSTRALIA & NEW ZEALAND ANAPHYLAXIS
TREATMENT MARKET FORECAST & PROSPECTS
6.3.4.7. REST OF ASIA-PACIFIC
6.3.4.7.1. REST OF ASIA-PACIFIC ANAPHYLAXIS TREATMENT
MARKET FORECAST & PROSPECTS
6.4. LATIN AMERICA
6.4.1. MARKET BY DRUG CLASS
6.4.2. MARKET BY ROUTE OF ADMINISTRATION
6.4.3. MARKET BY DISTRIBUTION CHANNEL
6.4.4. COUNTRY ANALYSIS
6.4.4.1. BRAZIL
6.4.4.1.1. BRAZIL ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.4.4.2. MEXICO
6.4.4.2.1. MEXICO ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.4.4.3. REST OF LATIN AMERICA
6.4.4.3.1. REST OF LATIN AMERICA ANAPHYLAXIS TREATMENT
MARKET FORECAST & PROSPECTS
6.5. MIDDLE EAST AND AFRICA
6.5.1. MARKET BY DRUG CLASS
6.5.2. MARKET BY ROUTE OF ADMINISTRATION
6.5.3. MARKET BY DISTRIBUTION CHANNEL
6.5.4. COUNTRY ANALYSIS
6.5.4.1. UNITED ARAB EMIRATES
6.5.4.1.1. UNITED ARAB EMIRATES ANAPHYLAXIS TREATMENT
MARKET FORECAST & PROSPECTS
6.5.4.2. SAUDI ARABIA
6.5.4.2.1. SAUDI ARABIA ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.5.4.3. ISRAEL
6.5.4.3.1. ISRAEL ANAPHYLAXIS TREATMENT MARKET FORECAST
& PROSPECTS
6.5.4.4. SOUTH AFRICA
6.5.4.4.1. SOUTH AFRICA ANAPHYLAXIS TREATMENT MARKET
FORECAST & PROSPECTS
6.5.4.5. REST OF MIDDLE EAST & AFRICA
6.5.4.5.1. REST OF MIDDLE EAST & AFRICA ANAPHYLAXIS TREATMENT
MARKET FORECAST & PROSPECTS
7. COMPETITIVE LANDSCAPE
7.1. MERCK & CO INC
7.1.1. OVERVIEW
7.1.2. PORTFOLIO
7.1.3. KEY STRENGTHS
7.1.4. KEY CHALLENGE
7.2. VIATRIS INC
7.2.1. OVERVIEW
7.2.2. PORTFOLIO
7.2.3. KEY STRENGTHS
7.2.4. KEY CHALLENGE
7.3. ALK-ABELLÓ
7.3.1. OVERVIEW
7.3.2. PORTFOLIO
7.3.3. KEY STRENGTH
7.3.4. KEY CHALLENGE
7.4. TEVA PHARMACEUTICALS LTD
7.4.1. OVERVIEW
7.4.2. PORTFOLIO
7.4.3. KEY STRENGTHS
7.4.4. KEY CHALLENGE
7.5. AMNEAL PHARMACEUTICALS
7.5.1. OVERVIEW
7.5.2. PORTFOLIO
7.5.3. KEY STRENGTHS
7.5.4. KEY CHALLENGES
7.6. PFIZER INC
7.6.1. OVERVIEW
7.6.2. PORTFOLIO
7.6.3. KEY STRENGTHS
7.6.4. KEY CHALLENGE
7.7. TEVA PHARMACEUTICAL INDUSTRIES LTD
7.7.1. OVERVIEW
7.7.2. PORTFOLIO
7.7.3. KEY STRENGTHS
7.7.4. KEY CHALLENGE
7.8. MANNKIND CORPORATION
7.8.1. OVERVIEW
7.8.2. PORTFOLIO
7.8.3. KEY STRENGTHS
7.8.4. KEY CHALLENGES
7.9. DMK PHARMACEUTICALS CORPORATION
7.9.1. OVERVIEW
7.9.2. PORTFOLIO
7.9.3. KEY STRENGTHS
7.9.4. KEY CHALLENGES
7.10. GSK PLC
7.10.1. OVERVIEW
7.10.2. PORTFOLIO
7.10.3. KEY STRENGTHS
7.10.4. KEY CHALLENGES
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1: GLOBAL
ANAPHYLAXIS TREATMENT MARKET, BY REGIONAL OUTLOOK, HISTORICAL YEARS, 2020-2023
(IN $ MILLION)
TABLE 2: GLOBAL
ANAPHYLAXIS TREATMENT MARKET, BY REGIONAL OUTLOOK, FORECAST YEARS, 2024-2032
(IN $ MILLION)
TABLE 3: REGULATORY
FRAMEWORK
TABLE 4: LIST OF
COLLABORATIONS
TABLE 5: LIST OF PRODUCT
LAUNCHES
TABLE 6: LIST OF
ACQUISITIONS
TABLE 7: LIST OF BUSINESS
DIVESTITURES & EXPANSIONS
TABLE 8: GLOBAL ANAPHYLAXIS
TREATMENT MARKET, BY DRUG CLASS, 2024-2032 (IN $ MILLION)
TABLE 9: GLOBAL
ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (IN $
MILLION)
TABLE 10: GLOBAL
ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2024-2032 (IN $ MILLION)
TABLE 11: GLOBAL
ANAPHYLAXIS TREATMENT MARKET, BY REGIONAL OUTLOOK, HISTORICAL YEARS, 2020-2023
(IN $ MILLION)
TABLE 12: GLOBAL
ANAPHYLAXIS TREATMENT MARKET, BY REGIONAL OUTLOOK, FORECAST YEARS, 2024-2032
(IN $ MILLION)
TABLE 13: NORTH AMERICA ANAPHYLAXIS
TREATMENT MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 14: NORTH AMERICA
ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS, 2024-2032 (IN $ MILLION)
TABLE 15: NORTH AMERICA
ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (IN $
MILLION)
TABLE 16: NORTH AMERICA
ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2024-2032 (IN $ MILLION)
TABLE 17: EUROPE
ANAPHYLAXIS TREATMENT MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 18: EUROPE
ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS, 2024-2032 (IN $ MILLION)
TABLE 19: EUROPE
ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (IN $
MILLION)
TABLE 20: EUROPE
ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2024-2032 (IN $ MILLION)
TABLE 21: ASIA-PACIFIC
ANAPHYLAXIS TREATMENT MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC
ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS, 2024-2032 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC
ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (IN $
MILLION)
TABLE 24: ASIA-PACIFIC
ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2024-2032 (IN $ MILLION)
TABLE 25: LATIN AMERICA
ANAPHYLAXIS TREATMENT MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 26: LATIN AMERICA ANAPHYLAXIS
TREATMENT MARKET, BY DRUG CLASS, 2024-2032 (IN $ MILLION)
TABLE 27: LATIN AMERICA
ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (IN $
MILLION)
TABLE 28: LATIN AMERICA
ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2024-2032 (IN $ MILLION)
TABLE 29: MIDDLE EAST AND
AFRICA ANAPHYLAXIS TREATMENT MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $
MILLION)
TABLE 30: MIDDLE EAST AND
AFRICA ANAPHYLAXIS TREATMENT MARKET, BY DRUG CLASS, 2024-2032 (IN $ MILLION)
TABLE 31: MIDDLE EAST AND
AFRICA ANAPHYLAXIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (IN
$ MILLION)
TABLE 32: MIDDLE EAST AND
AFRICA ANAPHYLAXIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2024-2032 (IN $
MILLION)
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: SUPPLY CHAIN ANALYSIS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY DRUG CLASS, 2023 & 2032 (IN %)
FIGURE 5: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY EPINEPHRINE, 2024-2032 (IN $ MILLION)
FIGURE 6: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY ANTI-HISTAMINE, 2024-2032 (IN $ MILLION)
FIGURE 7: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY BETA-ANTAGONIST, 2024-2032 (IN $ MILLION)
FIGURE 8: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY STEROID, 2024-2032 (IN $ MILLION)
FIGURE 9: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY OTHER DRUG CLASSES, 2024-2032 (IN $ MILLION)
FIGURE 10: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY ROUTE OF ADMINISTRATION, 2023 & 2032 (IN %)
FIGURE 11: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY PARENTERAL, 2024-2032 (IN $ MILLION)
FIGURE 12: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY ORAL, 2024-2032 (IN $ MILLION)
FIGURE 13: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY OTHER ROUTE OF ADMINISTRATION, 2024-2032 (IN $ MILLION)
FIGURE 14: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY DISTRIBUTION CHANNEL, 2023 & 2032 (IN %)
FIGURE 15: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY HOSPITAL PHARMACY, 2024-2032 (IN $ MILLION)
FIGURE 16: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY RETAIL PHARMACY, 2024-2032 (IN $ MILLION)
FIGURE 17: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY ONLINE PHARMACY, 2024-2032 (IN $ MILLION)
FIGURE 18: GLOBAL ANAPHYLAXIS TREATMENT MARKET,
BY REGIONAL OUTLOOK, 2023 & 2032 (IN %)
FIGURE 19: UNITED STATES ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 20: CANADA ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 21: UNITED KINGDOM ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 22: GERMANY ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 23: FRANCE ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 24: SPAIN ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 25: ITALY ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 26: POLAND ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 27: REST OF EUROPE ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 28: CHINA ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 29: JAPAN ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 30: INDIA ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 31: SOUTH KOREA ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 32: ASEAN COUNTRIES ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 33: AUSTRALIA & NEW ZEALAND
ANAPHYLAXIS TREATMENT MARKET 2024-2032 (IN $ MILLION)
FIGURE 34: REST OF ASIA-PACIFIC ANAPHYLAXIS
TREATMENT MARKET 2024-2032 (IN $ MILLION)
FIGURE 35: BRAZIL ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 36: MEXICO ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 37: REST OF LATIN AMERICA ANAPHYLAXIS
TREATMENT MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: UNITED ARAB EMIRATES ANAPHYLAXIS
TREATMENT MARKET 2024-2032 (IN $ MILLION)
FIGURE 39: SAUDI ARABIA ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 40: ISRAEL ANAPHYLAXIS TREATMENT MARKET
2024-2032 (IN $ MILLION)
FIGURE 41: SOUTH AFRICA ANAPHYLAXIS TREATMENT
MARKET 2024-2032 (IN $ MILLION)
FIGURE 42: REST OF MIDDLE EAST & AFRICA
ANAPHYLAXIS TREATMENT MARKET 2024-2032 (IN $ MILLION)